A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)

Inclusion Criteria:

• Age ≥ 18 years with a diagnosis of AD according to the AAD (American Academy ofDermatology) Consensus Criteria (2014) present for at least 12 months

• History of inadequate response to TCS of medium or higher potency (with or withoutTCI)

• EASI score ≥16

• vIGA-AD score ≥3

• ≥10% body surface area (BSA) of AD involvement

• Worst pruritus numerical rating scale ≥ 4

Exclusion Criteria:

• Treatment with a biological product within 12 weeks or 5 half-lives, whichever islonger, prior to Day 1

• Treatment with any of the following medications or therapies within 4 weeks or 5half-lives, whichever is longer, prior to Day 1:

• Systemic corticosteroids

• Nonbiologic, non-targeted Systemic immunosuppressants

• Phototherapy

• Janus kinase inhibitors

• Treatment with any of the following medications or therapies within 1 week, prior toDay 1:

• TCS

• TCI

• Topical phosphodiesterase type 4 inhibitors

• Other topical immunosuppressive agents

• Combination topical agents including TCS of any potency or TCI, PDE4inhibitors, or other topical immunosuppressive agents